Germany Legal Cannabis Market By Source (Marijuana, Hemp), By Cultivation (Indoor Cultivation, Greenhouse Cultivation, Outdoor Cultivation), By Derivatives (CBD, THC, Others), By End Use (Medical Use, Recreational Use, Industrial Use), By Region, Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 48.61 Million
CAGR (2026-2031)	12.84%
Fastest Growing Segment	Medical Use
Largest Market	South West
Market Size (2031)	USD 100.35 Million

Market Overview

The Germany Legal Cannabis Market will grow from USD 48.61 Million in 2025 to USD 100.35 Million by 2031 at a 12.84% CAGR. The Germany legal cannabis market encompasses medical cannabis available by prescription and limited adult-use cannabis for private cultivation and non-commercial cultivation associations, following the April 2024 Cannabis Act (CanG) and Medical Cannabis Act (MedCanG). Key drivers supporting market growth include affirmative legal advancements that have streamlined prescription processes and increased product acceptance, alongside enhanced patient access facilitated by telemedicine platforms. Furthermore, the growing adoption of cannabis for managing chronic diseases continues to fuel demand. According to the Federal Association of Pharmaceutical Cannabinoid Companies (BPC), in 2025, Germany's total legal medical cannabis sales reached approximately €2 billion.

Despite this expansion, a significant challenge impeding market growth is regulatory uncertainty, particularly concerning potential amendments to the Medical Cannabis Act. These proposed changes could introduce restrictions on new remote prescriptions and mail-order cannabis sales, impacting accessibility and potentially slowing the market's current trajectory.

Key Market Drivers

Regulatory Reforms Expand Access and Supply
The supportive regulatory framework and legalization enacted through the April 2024 Cannabis Act (CanG) and Medical Cannabis Act (MedCanG) have profoundly influenced the Germany legal cannabis market. These legislative changes reclassified cannabis as a non-narcotic and expanded the ability for physicians to prescribe medical cannabis, thereby creating a more accessible and regulated environment for both patients and industry participants. This impact is evidenced by the substantial increase in supply to meet growing demand. According to BfArM data, as reported by Natural Pharma in March 2026, Germany's medical cannabis imports surpassed 200 tonnes in 2025, marking a significant increase from 72 tonnes in 2024. This dramatic rise underscores the direct correlation between the new legal provisions and the expanded market activity.

Expanded Patient Access and Telemedicine-Driven Demand
Building upon these regulatory advancements, increasing patient access and prescriptions represent another critical driver for the German market. The streamlined prescription processes, alongside the growing acceptance of cannabis for various medical conditions, have directly facilitated greater patient reach. The emergence of telemedicine platforms has further enhanced accessibility, allowing more patients to receive consultations and prescriptions remotely. This expansion in patient access has led to a remarkable surge in demand. According to Bloomwell Group's Cannabis Barometer, as reported by Investing News Network in February 2026, medical cannabis prescriptions in Germany surged by 3,300 percent from March 2024 to December 2025. This demonstrates a fundamental shift in patient engagement with the regulated market. Furthermore, according to a Bloomwell analysis, in 2025, the average price per gram of medical cannabis flower in Germany experienced a notable reduction, falling from €8.33 in January to €5.23 in December.

Download Free Sample Report

Key Market Challenges

Regulatory uncertainty and telemedicine restrictions threaten patient access
A significant challenge impeding the growth of the Germany legal cannabis market is regulatory uncertainty, particularly concerning potential amendments to the Medical Cannabis Act. These proposed changes, which include restrictions on new remote prescriptions and mail-order cannabis sales, directly threaten patient access that has been a key market driver. The elimination or severe limitation of telemedicine platforms, which have streamlined the prescription process and expanded reach, would significantly reduce the number of patients able to access medical cannabis conveniently. This would stifle the market's current expansion trajectory by creating new barriers for individuals seeking treatment.

Unpredictability from restrictions undermining digital access and patient reach
The potential for such restrictions creates an environment of unpredictability for businesses operating in the sector. Efforts to enhance patient access through digital healthcare solutions would be undermined, leading to slower patient acquisition. For instance, according to the Federal Association of Pharmaceutical Cannabinoid Companies (BPC), as of 2025, an estimated 2,500 of Germany's licensed pharmacies sell medical cannabis. Restricting mail-order sales would force many patients to rely solely on physical pharmacy visits, decreasing the overall accessibility, particularly for those in rural areas or with limited mobility, thereby directly hampering continued market growth.

Key Market Trends

Diversification of Sourcing and Direct Imports
The German legal cannabis market is increasingly shaped by maturing supply chain dynamics, moving beyond simple import volumes to greater diversification of sourcing and improved logistical efficiencies. This trend is evident in the shift of import origins and the strengthening of direct supply channels. For instance, Canada's direct share of medical cannabis imports into Germany significantly increased, with Canadian producers shipping 93 tonnes directly to Germany in 2025, marking a 181% year-over-year growth and accounting for roughly half of all imports. This indicates a strategic evolution in how the market ensures consistent product availability, adapting to global supply shifts and optimizing distribution networks for a rapidly expanding patient base.

Rising Cross-Border Investments and Alliances
Another pivotal trend influencing the German legal cannabis market is the notable increase in cross-border investment and strategic alliances. This influx of foreign capital and collaborative ventures underscores growing international confidence in Germany's market potential, particularly as regulatory frameworks continue to develop. Such investments facilitate market consolidation and expansion of operational capabilities. A significant example is the acquisition of Sanity Group by Organigram for €250 million, a highly institutional deal reported in May 2026, which highlights the substantial financial commitments being made by international players to secure positions within the German market. These alliances are crucial for scaling operations and integrating global expertise.

Segmental Insights

Legislative Reforms and Telemedicine Drive Rapid Growth in Germany's Medical Cannabis Market Under BfArM Oversight
In the Germany Legal Cannabis Market, the Medical Use segment is experiencing rapid growth, positioning it as the fastest-growing sector. This surge is primarily driven by recent legislative reforms, notably the Cannabis Act (CanG) and the Medical Cannabis Act (MedCanG) enacted in 2024, which reclassified cannabis and significantly eased patient access to medicinal products. These changes reduced the administrative burden for physicians, enabling simpler prescription processes for various chronic conditions such as pain and multiple sclerosis. Furthermore, the increasing adoption of telemedicine platforms has expanded patient reach, while oversight by the Federal Institute for Drugs and Medical Devices (BfArM) ensures adherence to stringent quality standards, bolstering trust and widespread acceptance.

Regional Insights

Rhineland-Palatinate Drives Early, Regulated Cannabis Access in South West Germany
Within the evolving Germany Legal Cannabis Market, the South West emerges as a prominent region, partly due to specific state-level responsiveness to new legislation. Notably, Rhineland-Palatinate, a state in the South West, has demonstrated a proactive stance by being among the leading regions in issuing permits for Cannabis Cultivation Associations. This efficient implementation of the Cannabis Act by regional authorities, aligning with national guidelines from bodies like the Federal Institute for Drugs and Medical Devices (BfArM) for medical cannabis, facilitates earlier establishment and growth of regulated cannabis access points. This forward-thinking administrative approach contributes significantly to the region's strong positioning within the broader German legal cannabis landscape.

Recent Developments

• In January 2025, Aurora Cannabis launched its local brand, IndiMed, within the German medical cannabis market. This new product line consisted of medical cannabis cultivated in Germany's EU-GMP-certified facilities. The launch followed Aurora Cannabis receiving expanded cultivation and research and development licenses in 2024. The introduction of IndiMed further diversified the domestically produced medical cannabis offerings available to patients in Germany.
• In December 2024, two districts in Berlin, Friedrichshain-Kreuzberg and Neukölln, announced their intent to launch an adult-use cannabis pilot project in 2025. A company, in collaboration with Humboldt University, signed a letter of intent to organize the sale of cannabis through specialized stores. Participants, who had to be residents of these districts and part of a scientific study, would be able to purchase cannabis. This initiative was part of "Pillar 2" of Germany's cannabis legalization model, focusing on regional adult-use commerce pilot trials.
• In October 2024, German medical cannabis operator Sanity Group was preparing to supply and manage stores for a five-year adult-use cannabis sales pilot project in Frankfurt am Main. This development followed Germany's legalization of recreational cannabis earlier in the year, which paved the way for limited legal adult-use sales through such pilot projects. The project aimed to gather data and inform future drug policy, with approximately 4,000 residents expected to participate in Hanover and similar numbers anticipated in Frankfurt.
• In June 2024, Cansativa Group, a leading medical cannabis import and distribution platform in Germany, announced an exclusive partnership with the globally recognized cannabis brand, Cookies. This collaboration introduced a premium selection of cannabis products to the German medical cannabis market. The product line included four dried cannabis flower varieties, with the first, 'Apples and Bananas', becoming available nationwide in pharmacies by prescription starting August 1, 2024. This initiative allowed patients access to high-quality cannabis products meeting stringent EU-GMP and GACP standards.

Key Market Players

• Tilray Brands, Inc.
• Aurora Cannabis Inc.
• Canopy Growth Corporation
• Aphria Inc.
• Cronos Group Inc.
• Curaleaf Holdings, Inc.
• GW Pharmaceuticals plc
• Organigram Holdings Inc.
• HEXO Corp.
• Demecan GmbH

By Source	By Cultivation	By Derivatives	By End Use	By Region
Marijuana Hemp	Indoor Cultivation Greenhouse Cultivation Outdoor Cultivation	CBD THC Others	Medical Use Recreational Use Industrial Use	South-West North-West North-East South-East

Report Scope:

In this report, the Germany Legal Cannabis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Germany Legal Cannabis Market, By Source:

• Marijuana
• Hemp

• Germany Legal Cannabis Market, By Cultivation:

• Indoor Cultivation
• Greenhouse Cultivation
• Outdoor Cultivation

• Germany Legal Cannabis Market, By Derivatives:

• CBD
• THC
• Others

• Germany Legal Cannabis Market, By End Use:

• Medical Use
• Recreational Use
• Industrial Use

• Germany Legal Cannabis Market, By Region:

• South-West
• North-West
• North-East
• South-East